FindTrial
Sign In

Research on the signal transduction pathway of RAS on the atrial structural remodeling in atrial fibrillation.

Research on the signal transduction pathway of RAS on the atrial structural remodeling in atrial fibrillation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-CCC-14004220
Enrollment
Unknown
Registered
2014-01-23
Start date
2014-02-10
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

atrial fibrillation group:none
Control:NA

Sponsors

Tianjin Fifth Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Electrocardiogram: Atrial fibrillation, the patients are selected into the atrial fibrillation group. Electrocardiogram: sinus rhythm, the patients are selected into normal control group.

Exclusion criteria

Exclusion criteria: All patients who use angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonist drugs were excluded.

Design outcomes

Primary

MeasureTime frame
Collagen I;Collagen III;matrix metalloproteinase-;—

Countries

China

Contacts

Public ContactDu Xinping

Tianjin Fifth Central Hospital

xpdu2002@163.com+86 13820919967

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026